In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Bayer Japan Chief “Disappointed” at PMP Removal for Xarelto, Shows Eagerness for Add’l Indications
April 27, 2018
- Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry
April 27, 2018
- Otsuka’s Jynarque Earns FDA Nod for ADPKD at Second Attempt
April 26, 2018
- Encorafenib/Binimetinib Combo Filed in Japan: Ono
April 26, 2018
- Jitsubo Aims to Enter Contract-Manufacturing Business for Peptide Drug Substances
April 25, 2018
- Gilteritinib Filed in Japan, US for AML: Astellas
April 25, 2018
- Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
- Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
- Shionogi to Transfer Manufacturing Functions to Dedicated Unit
April 24, 2018
- Eisai Transfers European Prialt Rights to Riemser
April 24, 2018
- Top Court Favors Sandoz in Elplat Patent Suit
April 24, 2018
- Atozet, Zetia-Lipitor Combo, Now Available in Japan after Delay
April 24, 2018
- Dupixent Hits Japan Shelves: Sanofi
April 24, 2018
- Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?
April 24, 2018
- Japan Ethical Drug Sales in 54 Fields Shrink 1.6% in 2017
April 23, 2018
- Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup
April 19, 2018
- Astellas Sells Agensys Research Facilities to Kite
April 19, 2018
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit
April 19, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…